Personalized Medicine: DNA pioneers
Written by Brett Ruffell on March 10, 2016 for CanadianHealthcareNetwork.ca
Toronto pharmacy partners with genetic testing firm to assess potential for pharmacogenomics in community pharmacy.
Your pharmacist’s secret weapon: How your DNA can help perfect your medication
Catherine McLeod suffered one of her worst drug reactions – a minor stroke – while behind the wheel. She drove through a red light, and an oncoming vehicle totalled her car.
No one was seriously injured. But after the accident in 2005, she experienced two more minor strokes and kidney damage because of the litany of medications she was taking for bipolar disorder, diabetes and other conditions, she said. “I was overmedicated.”
Proposed Regulatory Framework for Direct-to-Consumer Genetic Testing: Diagnostics vs. Genetic Screening
Clinical Chemistry; September 18, 2014
On December 6, 2013, 23andMe stopped marketing direct-to- consumer (DTC)1 disease-predictive genetic testing to comply with the FDA’s directive. Although the FDA’s action was intended to protect the American public from questionable disease risk predictions, we believe the agency failed to assess all the benefits of DTC testing…
High genetic heterogeneity of Premature Ovarian Insufficiency
Integrated Healthcare Practitioners; June/July, 2014
Primary ovarian insufficiency greatly influences a woman’s fertility potential and her overall health.The condition affects about 1–2 % of women and in most cases, the cause is undefined. Primary ovarian insufficiency (POI) may be caused by any process that results in dysfunction or depletion of ovarian follicles, reducing the number of oocytes within the ovary…
Application of personalized medicine to chronic disease: a feasibility assessment
Clinical and Translational Medicine; December 18, 2013
Personalized Medicine has the potential to improve health outcomes and reduce the cost of care; however its adoption has been slow in Canada. Bridgepoint Health is a complex continuous care provider striving to reduce the burden of polypharmacy in chronic patients. The main goal of the study was to explore the feasibility of utilizing personalized medicine in the treatment of chronic complex patients as a preliminary institutional health technology assessment…
Falling prices and unfair competition in consumer genomics
Nature Biotechnology; September 10, 2013
In the November issue, Malorye Allison’s News Feature (Nat. Biotechnol. 30, 1027–1029, 2012) described the changing face of the direct-to-consumer (DTC) genomics industry. As founder and CEO of a DTC genomics company myself and an avid proponent of DTC, I was disturbed by 23andMe’s (Mountain View, CA, USA) announcement last year to cut the price of its genetic testing down to $99—a move I regard as stifling competition in what remains a small and nascent sector…
Reply to Just the facts, please
Nature Biotechnology; September 6, 2013
The intent of my letter of correspondence was to stir debate about the direct-to-consumer (DTC) genetic testing market. The DTC industry is being embraced by consumers, but is struggling to gain acceptance from a more skeptical community of medical professionals.
As an enthusiastic proponent of genetic testing for health improvement, I applaud the pioneering efforts of DTC companies like 23andMe (Mountain View, CA, USA) in educating consumers in the field of genetics…